Stramsen Biotech Inc. Announced $25 Million Funding Commitment from GEM Global Yield LLC SCS ("GEM")
Summary
HOUSTON, April 7, 2025 /PRNewswire/ -- Stramsen Biotech Inc, an emerging leader in plant-based biopharmaceutical industry, today announced that it has signed a binding agreement with GEM Global Yield LLC SCS ("GGY"), part of GEM, a Luxembourg-based private alternative investment group as its Lead Investor, for a $25 million share subscription facility to be funded annually over a 36-month term following a public listing of the Stramsens common stock. The funds secured through the share subscription facility will be strategically utilized to accelerate Stramsens growth trajectory and propel clinical development and recruitment of seasoned management and scientific teams.Stramsen will control the timing and maximum amount of drawdowns under this facility and has no minimum drawdown obligation. "This commitment from GEM validates Stramsen Biotechs vision of providing nature-based, sustainable, and affordable health solutions with minimal side effects to patients worldwide," said Scott Villwock, President and Chief Executive Officer of Stramsen Biotech.The $25 million facility from GGY will significantly support Stramsen Biotech Inc.s ambitious growth plans and empower the company to: Prepare for prospectus submission and ultimately pursue an Initial Public Offering (IPO), enhancing the companys financial position and market visibility. Invest in research and development of 33 innovative drug candidates, leveraging our natural plant-based approach to transform patient lives. Their competitive advantage lies in their proprietary, extensive medicinal plant database and world-class scientists and a robust pipeline of 33 drug candidates at various stages of development.About GEMGlobal Emerging Markets is a $3.4 billion alternative investment group that manages a diverse set of investment vehicles and has completed over 600 transactions in 72 countries.